30-Second Executive Brief
Executive Assessment
GSK functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A British pharmaceutical and vaccines company reporting Q2 2026 sales of £2.3 billion in Vaccines (+8%), led by Meningitis vaccines (+21%) and a more-than-doubling of Arexvy sales, alongside 14% growth in Specialty Medicines and double-digit gains across HIV, respiratory, and oncology. GSK's pipeline grew from 57 to 62 potential new vaccines and medicines between Q1 and Q2 2026, with plans to accelerate to 20+ Phase III trial starts in 2026 across oncology, respiratory, hepatology, and vaccines.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Defense — $3,805,378: THIS REQUIREMENT IS FOR THREAT INFORMATION FILE (TIF) DATA ANALYSIS SERVICES.
USAspending.gov · Sep 22, 2024
Department of Health and Human Services — $602,722: DUNLAP, BENNETT & LUDWIG, PLLC:1301794 [24-002794]
USAspending.gov · Aug 26, 2023
General Services Administration — $480,275: DESIGN/BUILD COOLING TOWER TO REPLACE EXISTING AT DICK CHENEY FEDERAL BUILDING, 100 EAST B STREET, CASPER, WY 82601
USAspending.gov · Sep 13, 2024
Department of Defense — $239,725: REPLACE GREASE TRAP BUILDING 1755
USAspending.gov · May 1, 2026
Department of Health and Human Services — $194,259: TRADEMARK-RELATED SERVICES AWARD TO DUNLAP, BENNETT & LUDWIG, PLLC
USAspending.gov · Aug 26, 2023
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- TipRanks / The Globe and Mail — GSK starts 2026 with strong Q1, backs outlooknews
- GSK — GSK delivers strong Q2 core results, accelerates R&D pipelinecompany
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding GSK — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Arexvy's swing from softness to more-than-doubling in one quarter is a reminder of how volatile RSV-vaccine demand can be
31% confidenceGSK's Arexvy RSV vaccine sales more than doubled in Q2 2026 after prior softness, contributing to 8% overall Vaccines segment growth alongside 21% Meningitis vaccine growth.
This is InsightNodes' own interpretive read: RSV vaccine demand appears to be more seasonally and competitively volatile quarter-to-quarter than GSK's more established vaccine franchises, likely reflecting a combination of insurance-coverage timing, competitive dynamics with other RSV vaccine makers, and immunization-season patterns -- this means Arexvy's quarterly figures should be read with more caution than steadier franchises like Meningitis, and GSK's ability to smooth this volatility (through better demand forecasting or broader indication expansion) will matter for how reliably Vaccines segment growth can be modeled going forward.
InsightNodes analysis of GSK Q2 2026 results · Aug 14, 2026
GSK's Timeline
A sourced, dated history of GSK's key moments — founding to present.
Apr 2026 · Q1 2026: sales up 5% to £7.6 billion
GSK reported Q1 2026 sales rising 5% at constant exchange rates to £7.6 billion, driven by 14% growth in Specialty Medicines and double-digit gains in HIV, respiratory, and oncology.
Jul 2026 · Q2 2026: accelerates R&D, plans 20+ Phase III starts
GSK reported strong Q2 2026 core results and announced plans to accelerate its R&D and late-stage pipeline, targeting more than 20 Phase III trial starts in 2026.